 |
 Video: What is a Stock Split?
|
|
|
| Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD. According to our GMTX stock split history records, GMTX has had 0 splits. | |
|
GMTX (GMTX) has 0 splits in our GMTX stock split history database.
Looking at the GMTX stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into GMTX shares, starting with a $10,000 purchase of GMTX, presented on a split-history-adjusted basis factoring in the complete GMTX stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/13/2020 |
|
| End date: |
12/29/2022 |
|
| Start price/share: |
$10.54 |
|
| End price/share: |
$1.35 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-87.19% |
|
| Average Annual Total Return: |
-57.86% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,280.83 |
|
| Years: |
2.38 |
|
|
|
|
|
